Europe looks increasingly likely to follow America’s lead and require drug companies to test their products in children. But Europe's pharma lack the resources to carry out drug trials in children — so industry and patients will have to rely on the skills developed in academic centres.
Imperial College London's technology commercialisation company is betting on a spin-out company, deltaDOT, to speed detection and decrease costs of finding new proteins for drug discovery.
Scientists love to complicate things; and if you're not in the same field, or – worse – are in business or investment, then it's easy to get lost. Enter the Science|Business Quick Guides to some of the hottest fields of science and technology…
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.